Anzeige
Mehr »
Login
Montag, 13.07.2020 Börsentäglich über 12.000 News von 632 internationalen Medien
Die News der News! Mehrere Hundert Prozent Kursgewinn am Montag?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1423S ISIN: ES0169501030 Ticker-Symbol: PMR 
Tradegate
10.07.20
17:57 Uhr
9,700 Euro
+0,025
+0,26 %
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
9,7459,92012.07.
9,7659,87010.07.

Aktuelle News zur PHARMAMAR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 1 July and 7 July 2020.15
02.07.PHARMA MAR, S.A.: The Company announces that its partner in South Korea, Boryung Pharmaceutical, has presented the results of in vitro studies of plitidepsin (Aplidin) in SARS-CoV-2.50
02.07.BRIEF-Pharma Mar: Boryung Pharmaceutical Announces Superior Potent Results For Plitidepsin Against Sars-Cov-215
PHARMAMAR Aktie jetzt für 0€ handeln
01.07.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 24 June and 30 June 2020.10
29.06.BRIEF-Pharma Mar's Lurbinectedin Receives Acceptance For Clinical Trial Application In China5
29.06.BRIEF-Pharma Mar Receives Payment Of 100 Mln Dollars From Jazz Pharmaceuticals For Lurbinectedin US Approval9
25.06.XFRA DIVIDEND/INTEREST INFORMATION - 26.06.2020 - 11.653FOLGENDE WERTPAPIERE WERDEN AM 25.06.2020 CUM DIVIDENDE/ZINSEN UND AM 26.06.2020 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 25.06.2020. THE EX-DIVIDEND/INTEREST...
► Artikel lesen
24.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 17 June and 23 June 2020.9
18.06.PHARMA MAR, S.A.: The Board of Directors agrees to execute the reverse share split agreed by the General Shareholders' Meeting.12
18.06.PHARMA MAR, S.A.: It is reported that all proposed resolutions submitted by the Board to the General Shareholders' Meeting have been approved.1
18.06.PHARMA MAR, S.A.: The Company informs about the dividend payment6
18.06.PHARMA MAR, S.A.: Attached is a copy of the presentation to shareholders to be made at the General Shareholders' Meeting of Pharma Mar by the Chairman of the Company.8
17.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 10 June and 16 June 2020.4
17.06.PharmaMar gibt die US-amerikanische FDA-Zulassung von Lurbinectedin (Zepzelca) für die Behandlung von metastasierendem kleinzelligem Lungenkrebs bekannt488Madrid (ots/PRNewswire) - - Lurbinectedin ist im Rahmen eines "beschleunigten Zulassungsverfahrens" zugelassen worden, basierend auf der Gesamtansprechrate und der Dauer des Ansprechens, die in einer...
► Artikel lesen
16.06.PharmaMar shares jump after FDA approves first lung cancer treatment for 22 years10
16.06.PharmaMar Announces the U.S. FDA Approval of lurbinectedin (Zepzelca) for the Treatment of Metastatic Small Cell Lung Cancer305- Lurbinectedin is approved under "Accelerated Approval" based on overall response rate and duration of response demonstrated in an open-label, monotherapy clinical trial. - The anti-tumor...
► Artikel lesen
16.06.Jazz, PharmaMar get FDA accelerated approval for Zepzelca in metastatic SCLC9
16.06.BRIEF-Pharma Mar: US FDA Approves Lurbinectedin To Treat Metastatic Small Cell Lung Cancer16
15.06.PHARMA MAR, S.A.: Pharma Mar reports that the FDA has approved lurbinectedin for the treatment of metastatic small cell lung cancer under "accelerated approval" regulation.7
10.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 3 June and 9 June 2020.8
Seite:  Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3